The Farnesoid X Receptor (FXR) Agonist EDP-305 Inhibits Fibrosis Progression in a Rat Model of Nonalcoholic Steatohepatitis Cirrhosis

Sarani Ghoshal¹, Gunisha Arora¹, Ricard Masia², Diego S. Ferriera³, Mozhdeh Sojoodi¹, Yang Li⁴, Guogiang Wang⁴, Yat Sun Or⁴, Li-Juan Jiang⁴, Kenneth K. Tanabe¹. Bryan C. Fuchs¹

ENANTA
Pharmaceuticals

¹Division of Surgical Oncology, ²Department of Pathology, ³Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States ⁴Enanta Pharmaceuticals, Inc., Watertown, MA, USA



Background: Farnesoid X Receptor


Farnesoid X receptor (FXR) is a nuclear receptor that has emerged as a key regulator in the maintenance of bile acid homeostasis.

FXR agonists are currently under clinical investigation for the management of various liver diseases such as primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).

However, most preclinical studies have examined the effects of FXR agonists in mouse models where fibrosis progression to cirrhosis is challenging.


Here, we investigate the anti-fibrotic effects of the FXR agonist EDP-305 in a rat model of NASH cirrhosis.

CDAHFD Fed Rats Develop Bridging Fibrosis and Cirrhosis Reminiscent of Late-Stage F3-4 Human Disease




When fed to mice, the L-amino acid-defined, high fat diet with 60 kcal% fat and 0.1% methionine (CDAHFD) induces a severe fibrotic response. However, the collagen deposition patterns in a "chicken-wire" format similar to other mouse models and reminiscent of early human disease. By comparison, rats fed the CDAHFD developed bridging fibrosis by 6 weeks that progressed to nodular cirrhosis by 12 weeks, reminiscent of late-stage human disease.

CDAHFD-Induced Rat Model of NASH Cirrhosis with EDP-305 Treatment




Male Wistar rats (175-200 g) were fed either normal chow (NC) or CDAHFD for 12 weeks. Animals were randomized to receive either EDP-305 30mg/kg or vehicle control (0.5% methylcellulose (MC)) at the start of week 5 (n = 8 per group).

EDP-305 Treatment was Well Tolerated in the CDAHFD Rat Model




EDP-305 was well tolerated in CDAHFD rats as indicated by no change in body weight compared to MC. EDP-305 increased liver *Shp* gene expression and decreased liver *Cyp7a1* gene expression indicative of FXR agonism.

EDP-305 Treatment Improved Liver Function in CDAHFD Rat Model




EDP-305 treatment decreased serum ALT suggestive of reduced hepatic injury.

EDP-305 Treatment Reduced Fibrosis



Rats fed CDAHFD developed nodular cirrhosis. EDP-305 significantly decreased fibrosis in CDAHFD fed rats as assessed by Sirius red staining.

EDP-305 Treatment Reduced Fibrosis



EDP-305 30 mpk reduced fibrosis as assessed by morphometric quantification of the collagen proportional area (CPA) in Sirius Red stained liver sections and HPLC measurement of Hydroxy-Proline levels in liver tissue. qPCR further confirmed reduced expression of *Col1A1* after EDP-305 treatment.

Conclusion

In a rat model of NASH cirrhosis that more closely resembles the human histology, EDP-305 reduced fibrosis progression.

These results suggest that EDP-305 may have potent anti-fibrotic effects in late-stage F3/4 patients.